Phase III trials involving Gardasil, the HPV vaccine promoted for women, has been shown to protect young males from HPV virus that can lead to cancer. The manufacturer of Gardasil, Merck, now seeks FDA approval for use of the vaccine in young males, age nine to twenty-six. Merck is also awaiting FDA approval for Giardisil use in women age 27 to 45.
Gardasil use in male youths is proposed for the prevention of genital warts and other HPV virus related communicable lesions. Merck's most recent study shows that ninety-percent less boys and young men developed HPV related lesions after receiving the Gardasil vaccine.
A mathematical study, published last year in the New England Journal of Medicine, showed that widespread vaccination of women with Gardasil would be less cost effective than screening programs, a detail that has obviously not deterred Merck from promoting Gardasil. Young males are Merck's newest target for Gardasil vaccination. read more at emaxhealth